Zymeworks Inc. (NASDAQ:ZYME) stock is surging on Monday, with a session volume of 2.17 million, compared to an average volume of 728.75K, according to Benzinga Pro.Zymework, along with its partners, Jazz Pharmaceuticals Inc. (NASDAQ:JAZZ) and BeOne Medicines Inc. (NASDAQ:ONC) , announced topline results from the Phase 3 HERIZON-GEA-01 trial.The study evaluated Ziihera (zanidatamab-hrii) in combination with chemotherapy, with or without BeOne’s Tevimbra (tislelizumab), as a first-line treatment for HER2-posi ...